NEW YORK (360Dx) – BioDirection said Thursday that it has inked an exclusive worldwide license for development of its Tbit diagnostic platform to diagnose and monitor sepsis.

The agreement is an extension of a deal in place since 2012 when BioDirection licensed a portfolio of 14 patents from quantum-dot company Nanosys for development of a diagnostic platform to detect traumatic brain injury at the point of care.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.